Sarepta Therapeutics
Stock Forecast, Prediction & Price Target
Sarepta Therapeutics (SRPT) stock Price Target by analysts
Sarepta Therapeutics (SRPT) stock Price Target by analysts
Average Price Target
$181.8
Potential upside: 818.18%
Sarepta Therapeutics price prediction
What is Sarepta Therapeutics stock analysts` prediction?
Sarepta Therapeutics stock forecast: Based on 5 Wall Street analysts` predicted price targets for Sarepta Therapeutics in the last 3 months, the avarage price target is $181.8, with a high forecast of $NaN. The average price target represents a 818.18% change from the last price of $19.8.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Sarepta Therapeutics stock Price Target by analysts
Full breakdown of analysts given Sarepta Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Gil Blum Needham | 0% 0/3 | 10 months ago | $202 920.20% upside | $136.87 | StreetInsider | Previous targets (2) |
Biren Amin Piper Sandler | 0% 0/4 | 10 months ago | $182 819.19% upside | $136.87 | StreetInsider | Previous targets (3) |
Brian Skorney Robert W. Baird | 0% 0/3 | 11 months ago | $193 874.74% upside | $124.95 | StreetInsider | Previous targets (2) |
Kristen Kluska Cantor Fitzgerald | 0% 0/1 | 11 months ago | $167 743.43% upside | $124.95 | StreetInsider | Previous targets (0) |
Andrew Tsai Jefferies | 0% 0/1 | 11 months ago | $165 733.33% upside | $127.08 | StreetInsider | Previous targets (0) |
Gavin Clark-Gartner Evercore ISI | 0% 0/2 | about 1 year ago | $179 804.04% upside | $136.4 | StreetInsider | Previous targets (1) |
Biren Amin Piper Sandler | 0% 0/4 | about 1 year ago | $200 910.10% upside | $140.06 | TheFly | Previous targets (3) |
Brian Abrahams RBC Capital | 0% 0/5 | about 1 year ago | $181 814.14% upside | $140.06 | StreetInsider | Previous targets (4) |
Gena Wang Barclays | 0% 0/2 | about 1 year ago | $203 925.25% upside | $140.06 | TheFly | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/5 | about 1 year ago | $182 819.19% upside | $147.88 | StreetInsider | Previous targets (4) |
Kostas Biliouris BMO Capital | 0% 0/2 | about 1 year ago | $200 910.10% upside | $154.79 | StreetInsider | Previous targets (1) |
Biren Amin Piper Sandler | 0% 0/4 | over 1 year ago | $205 935.35% upside | $156.91 | StreetInsider | Previous targets (3) |
Gavin Clark-Gartner Evercore ISI | 0% 0/2 | over 1 year ago | $185 834.34% upside | $160.72 | TheFly | Previous targets (1) |
Uy Ear Mizuho Securities | 0% 0/3 | over 1 year ago | $200 910.10% upside | $165.13 | StreetInsider | Previous targets (2) |
Brian Skorney Robert W. Baird | 0% 0/3 | over 1 year ago | $200 910.10% upside | $171.35 | StreetInsider | Previous targets (2) |
Gena Wang Barclays | 0% 0/2 | over 1 year ago | $185 834.34% upside | $119.98 | TheFly | Previous targets (1) |
Brian Skorney Robert W. Baird | 0% 0/3 | over 1 year ago | $170 758.58% upside | $124 | TheFly | Previous targets (2) |
Biren Amin Piper Sandler | 0% 0/4 | over 1 year ago | $157 692.92% upside | $119.98 | StreetInsider | Previous targets (3) |
Kostas Biliouris BMO Capital | 0% 0/2 | over 1 year ago | $170 758.58% upside | $117.44 | StreetInsider | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/5 | over 1 year ago | $142 617.17% upside | $123.46 | StreetInsider | Previous targets (4) |
Brian Abrahams RBC Capital | 0% 0/5 | over 1 year ago | $157 692.92% upside | $130.7 | TheFly | Previous targets (4) |
Uy Ear Mizuho Securities | 0% 0/3 | over 1 year ago | $179 804.04% upside | $132.74 | StreetInsider | Previous targets (2) |
Hartaj Singh Oppenheimer | 33.33% 1/3 | over 1 year ago | $180 809.09% upside | $131.7 | StreetInsider | Previous targets (2) |
Matthew Harrison Morgan Stanley | 0% 0/2 | over 1 year ago | $165 733.33% upside | $135.04 | StreetInsider | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/5 | over 1 year ago | $141 612.12% upside | $130.9 | StreetInsider | Previous targets (4) |
Matthew Harrison Morgan Stanley | 0% 0/2 | over 2 years ago | $187 844.44% upside | $145.01 | Benzinga | Previous targets (1) |
Unknown Credit Suisse | N/A | over 2 years ago | $114 475.75% upside | $117.53 | Benzinga | N/A |
Unknown Needham | N/A | over 2 years ago | $160 708.08% upside | $117.53 | Benzinga | N/A |
Unknown BTIG | N/A | almost 3 years ago | $160 708.08% upside | $132.13 | Benzinga | N/A |
Unknown UBS | N/A | almost 3 years ago | $158 697.97% upside | $123.56 | Benzinga | N/A |
Gil Blum Needham | 0% 0/3 | almost 3 years ago | $158 697.97% upside | $105.01 | TipRanks Contributor | Previous targets (2) |
Unknown Morgan Stanley | N/A | about 3 years ago | $135 581.81% upside | $116.57 | Benzinga | N/A |
Hartaj Singh Oppenheimer | 33.33% 1/3 | about 3 years ago | $150 657.57% upside | $109 | Pulse 2.0 | Previous targets (2) |
Unknown Morgan Stanley | N/A | about 3 years ago | $100 405.05% upside | $95.2 | Benzinga | N/A |
Unknown Needham | N/A | about 3 years ago | $162 718.18% upside | $93.96 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | about 3 years ago | $80 304.04% upside | $84.04 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $155 682.82% upside | $68.84 | Benzinga | N/A |
Zhiqiang Shu Berenberg Bank | 100% 1/1 | over 3 years ago | $94 374.74% upside | $79.56 | TipRanks Contributor | Previous targets (0) |
Gil Blum Needham | 0% 0/3 | over 3 years ago | $150 657.57% upside | $79.56 | TipRanks Contributor | Previous targets (2) |
Uy Ear Mizuho Securities | 0% 0/3 | over 3 years ago | $160 708.08% upside | $76.15 | TipRanks Contributor | Previous targets (2) |
Yun Zhong BTIG | 100% 1/1 | over 3 years ago | $125 531.31% upside | $84.09 | TipRanks Contributor | Previous targets (0) |
Hartaj Singh Oppenheimer | 33.33% 1/3 | over 3 years ago | $125 531.31% upside | $89.16 | StreetInsider | Previous targets (2) |
Judah Frommer Credit Suisse | 100% 1/1 | almost 4 years ago | $95 379.79% upside | $84.19 | TheFly | Previous targets (0) |
Sarepta Therapeutics Financial Estimates
Sarepta Therapeutics Revenue Estimates
Sarepta Therapeutics EBITDA Estimates
Sarepta Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $701.88M N/A | $933.01M 32.92% | $1.24B 33.26% | Avg: $3.12B Low: $2.31B High: $4.11B avg. 151.19% | Avg: $3.71B Low: $2.97B High: $4.69B avg. 19.07% | Avg: $4.31B Low: $3.45B High: $5.44B avg. 16.04% | Avg: $4.62B Low: $3.70B High: $5.82B avg. 7.10% |
Net Income
% change YoY
| $-418.78M N/A | $-703.48M -67.98% | $-535.97M 23.81% | Avg: $994.29M Low: $48.04M High: $1.78B avg. 285.51% | Avg: $1.32B Low: $108.10M High: $2.00B avg. 33.60% | Avg: $1.44B Low: $1.07B High: $1.94B avg. 9.02% | Avg: $1.62B Low: $1.20B High: $2.17B avg. 11.99% |
EBITDA
% change YoY
| $-412.11M N/A | $-473.53M -14.90% | $-439.19M 7.25% | Avg: $-2.05B Low: $-2.70B High: $-1.52B avg. -367.91% | Avg: $-2.44B Low: $-3.08B High: $-1.96B avg. -19.07% | Avg: $-2.83B Low: $-3.58B High: $-2.27B avg. -16.04% | Avg: $-3.04B Low: $-3.83B High: $-2.43B avg. -7.10% |
EPS
% change YoY
| -$5.15 N/A | -$8.03 -55.92% | -$5.8 27.77% | Avg: $11.35 Low: $0.52 High: $19.36 avg. 295.65% | Avg: $12.8 Low: $1.17 High: $21.66 avg. 12.79% | Avg: $15.68 Low: $11.62 High: $21 avg. 22.46% | Avg: $17.56 Low: $13.02 High: $23.52 avg. 11.99% |
Operating Expenses
% change YoY
| $1.05B N/A | $1.32B 26.04% | $1.36B 2.37% | Avg: $1.63B Low: $1.21B High: $2.14B avg. 19.82% | Avg: $1.94B Low: $1.55B High: $2.44B avg. 19.07% | Avg: $2.25B Low: $1.80B High: $2.84B avg. 16.04% | Avg: $2.41B Low: $1.93B High: $3.04B avg. 7.10% |
FAQ
What is Sarepta Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 85.03% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is 48.04M, average is 994.29M and high is 1.78B.
What is Sarepta Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 48.35% in 2025-2028.
We have gathered data from 14 analysts. Their low revenue estimate is $2.31B, average is $3.12B and high is $4.11B.
What is Sarepta Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 85.72% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is $0.52, average is $11.35 and high is $19.36.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering Sarepta Therapeutics stock. The most successful analyst is Gil Blum.